Ovulation Induction with Clomid and Letrozole: A Complete Guide

Ovulation induction refers to the use of medication to stimulate the development and release of eggs from the ovaries. In a normal menstrual cycle, the brain releases hormones (FSH and LH) that cause one follicle in the ovary to mature and release an egg — this is ovulation. In women who do not ovulate regularly (anovulation) or who ovulate inconsistently, oral medications can restore or enhance this process.

The concept has a long history. Clomiphene citrate was first approved by the US FDA in 1967 and has been the most prescribed fertility drug in the world for over five decades. Letrozole, originally developed as a breast cancer medication, emerged as a fertility treatment in the early 2000s when researchers discovered its ability to stimulate ovulation with fewer side effects. A landmark 2014 trial published in the New England Journal of Medicine established letrozole as superior to clomiphene for women with PCOS, and it has since become the recommended first-line agent by both ASRM and NICE guidelines.

Ovulation induction can be used as a standalone treatment (with timed intercourse) or combined with intrauterine insemination (IUI) for enhanced effectiveness.

Ovulation induction is not appropriate for every fertility patient, but it is the right starting point for a substantial proportion of women seeking help. Your fertility specialist may recommend it if you fall into one or more of these categories.

Polycystic Ovary Syndrome (PCOS)

PCOS is the single most common reason for ovulation induction. It affects an estimated 8-13% of reproductive-age women globally, and prevalence in India may be even higher — studies suggest 9-36% depending on the diagnostic criteria and population studied. PCOS disrupts the hormonal signals needed for regular ovulation, leading to irregular or absent periods and difficulty conceiving.

Ovulation induction with letrozole is now the internationally recommended first-line medical treatment for anovulatory infertility in PCOS. The landmark NICHD trial (Legro et al., 2014) demonstrated that letrozole produced significantly higher ovulation rates (61.7% vs 48.3%) and live birth rates (27.5% vs 19.1%) compared to clomiphene in women with PCOS.

Anovulation (Non-PCOS)

Some women do not ovulate regularly for reasons other than PCOS. These include hypothalamic dysfunction (often related to stress, low body weight, or excessive exercise), mild hyperprolactinaemia, or idiopathic anovulation. Ovulation induction can restore regular ovulation in many of these cases.

Unexplained Infertility

When all standard fertility investigations — semen analysis, ovulation assessment, tubal patency tests, and basic hormonal panels — reveal no identifiable cause, ovulation induction combined with timed intercourse or IUI is a well-established first-line approach. Even in women who appear to ovulate normally, mild stimulation can improve cycle regularity, follicle development, and the timing of ovulation, modestly increasing the chance of conception.

Mild Male Factor Infertility

When semen analysis shows mildly reduced parameters but the post-wash total motile sperm count (TMSC) remains above 10 million, ovulation induction combined with IUI can compensate for mild male factor by ensuring optimal egg availability at the time of insemination.

Luteal Phase Defects

Some women ovulate but have inadequate progesterone production in the second half of the cycle (the luteal phase), which can impair implantation. Ovulation induction medications, particularly clomiphene, can improve luteal phase quality by promoting stronger ovulation.

Two oral medications dominate ovulation induction worldwide. Understanding how they work, their differences, and which is better suited to your situation is essential.

Clomiphene Citrate (Clomid)

How it works: Clomiphene is a selective oestrogen receptor modulator (SERM). It blocks oestrogen receptors in the hypothalamus, tricking the brain into thinking oestrogen levels are low. The brain responds by releasing more FSH (follicle-stimulating hormone), which stimulates the ovaries to develop follicles and produce eggs.

Typical protocol: 50-150 mg daily for 5 days, starting on cycle day 2, 3, or 5. The starting dose is usually 50 mg, increasing in subsequent cycles if ovulation does not occur.

Advantages:

• Longest track record of any fertility drug (in use since the 1960s)
• Extremely well-studied with extensive safety data
• Very affordable (Rs 50-300 per cycle in India)
• Available at virtually every pharmacy in India

Disadvantages:

• Anti-oestrogenic effects on the endometrium can thin the uterine lining, potentially reducing implantation rates
• Anti-oestrogenic effects on cervical mucus can make it hostile to sperm
• Higher rate of side effects: hot flushes (10-20%), mood changes, headaches, and rarely visual disturbances
• Higher multiple pregnancy rate compared to letrozole
• A "discrepancy" between ovulation rates (60-80%) and pregnancy rates (30-40% over 6 cycles) partly due to its anti-oestrogenic effects on the endometrium and cervical mucus

Letrozole (Femara)

How it works: Letrozole is an aromatase inhibitor. It works by blocking the enzyme aromatase, which converts androgens to oestrogen. The resulting temporary drop in oestrogen triggers the brain to release more FSH, stimulating follicle development. Critically, letrozole's effects are short-lived, and once the medication is stopped, oestrogen levels recover quickly — meaning the endometrium and cervical mucus are not adversely affected.

Typical protocol: 2.5-7.5 mg daily for 5 days, starting on cycle day 2 or 3. The starting dose is usually 2.5 mg, with increases to 5 mg or 7.5 mg in subsequent cycles if needed.

Advantages:

• Higher pregnancy and live birth rates compared to clomiphene (demonstrated in the landmark NICHD trial)
• No anti-oestrogenic effects on the endometrium — maintains or improves endometrial thickness
• No adverse effects on cervical mucus
• Lower multiple pregnancy rate (tends to produce single dominant follicle)
• Fewer side effects overall
• Short half-life (cleared from the body quickly)
• Now recommended as first-line by ASRM, NICE, and international guidelines for PCOS

Disadvantages:

• Slightly more expensive than clomiphene (though still very affordable: Rs 150-500 per cycle)
• Off-label use for fertility (approved for breast cancer; used off-label for ovulation induction)
• Less extensive long-term safety data compared to clomiphene, though existing evidence is reassuring
• Not universally available at all pharmacies (though widely available at most)

Head-to-Head Comparison

Data from Legro RS et al., NEJM 2014 (NICHD Reproductive Medicine Network trial)

Which Should You Choose?

For most women — particularly those with PCOS — letrozole is now the recommended first-line medication based on strong evidence. Guidelines from ASRM (2017), NICE (CG156, updated), and the international evidence-based guideline for PCOS (2018, updated 2023) all recommend letrozole as first-choice.

Clomiphene remains a reasonable alternative when letrozole is not available, not tolerated, or when a clinician has specific clinical reasons to prefer it. Some doctors in India still use clomiphene as first-line due to familiarity and long experience, though this practice is evolving as letrozole evidence becomes more widely adopted.

Understanding the process helps reduce anxiety and set realistic expectations. Here is a detailed walkthrough of a typical ovulation induction cycle.

Step 1: Baseline Assessment (Cycle Day 2-3)

Before starting medication, your doctor will perform a baseline evaluation on day 2 or 3 of your menstrual period:

• Transvaginal ultrasound: Checks for ovarian cysts (which may need to resolve before starting), counts antral follicles (a marker of ovarian reserve), and assesses baseline endometrial thickness
• Blood tests: FSH, LH, oestradiol (E2), and possibly AMH (anti-Mullerian hormone) to assess ovarian reserve
• Semen analysis: If not already done, your partner's sperm should be assessed before starting treatment
• Tubal patency: An HSG (hysterosalpingography) or sonosalpingography should confirm at least one open fallopian tube (essential if planning timed intercourse or IUI)
• General health: Thyroid function (TSH), prolactin levels, and metabolic screening (particularly for PCOS patients)

If the baseline assessment is satisfactory, your doctor will prescribe the medication and explain the cycle plan.

Step 2: Medication Protocol (Cycle Day 2-7 or 3-7)

You will take the prescribed oral medication for 5 days:

Letrozole protocol:

• Starting dose: 2.5 mg daily for 5 days
• If no ovulation: increase to 5 mg, then 7.5 mg in subsequent cycles
• Maximum dose: 7.5 mg daily (some specialists go up to 10 mg, though this is less standard)

Clomiphene protocol:

• Starting dose: 50 mg daily for 5 days
• If no ovulation: increase to 100 mg, then 150 mg in subsequent cycles
• Maximum dose: 150 mg daily (doses above this are rarely used)

The medication is taken orally, usually at the same time each day. Some doctors prefer cycle day 2-6, others day 3-7 or day 5-9 — the evidence does not show a significant difference in outcomes between these starting days, so your doctor will choose based on their practice preference.

Step 3: Monitoring (Cycle Day 10-14)

After completing the medication course, you will return for monitoring to assess your response:

• Follicle tracking ultrasound: A transvaginal ultrasound checks the number and size of developing follicles. The goal is one to two mature follicles (18-22 mm in diameter). More than three mature follicles may warrant cycle cancellation due to multiple pregnancy risk.
• Endometrial assessment: The uterine lining thickness is measured. A thickness of 7 mm or more is generally considered adequate for implantation.
• Timing determination: Based on follicle size, your doctor will determine when ovulation is likely and plan the next step accordingly.

Some doctors perform minimal monitoring (one ultrasound), while others do serial scans. The level of monitoring depends on clinical practice, your response to medication, and whether you are combining ovulation induction with IUI.

Step 4: Trigger Shot (if needed)

When the lead follicle reaches 18-22 mm, your doctor may administer a trigger injection to ensure ovulation occurs at a predictable time:

• hCG injection (Pregnyl, Ovidrel, or generic): 5,000-10,000 IU intramuscular or 250 mcg subcutaneous. This mimics the natural LH surge and triggers ovulation approximately 36-40 hours later.
• Not always required: Some women on ovulation induction will ovulate naturally without a trigger. Your doctor may monitor for a natural LH surge using blood tests or urine ovulation predictor kits (OPKs).

The trigger shot serves two purposes: it ensures ovulation occurs and it allows precise timing for intercourse or IUI.

Step 5: Timed Intercourse or IUI

Based on the trigger shot timing, your doctor will advise:

• Timed intercourse: Sexual intercourse is recommended on the day of the trigger shot and/or 24-36 hours after. Some doctors recommend intercourse every other day around the expected ovulation window.
• IUI (intrauterine insemination): If combining ovulation induction with IUI, the insemination is typically scheduled 24-36 hours after the trigger shot. Washed, concentrated sperm are placed directly in the uterus using a thin catheter.

After ovulation, your doctor may prescribe progesterone supplementation (oral, vaginal suppositories, or injections) to support the uterine lining during the luteal phase (the two-week wait).

A blood pregnancy test (beta-hCG) is scheduled 14-16 days after ovulation or the trigger shot.

Understanding realistic success rates is critical for setting appropriate expectations. Ovulation induction is effective, but it is not a guaranteed solution — most couples need multiple cycles.

Per-Cycle Success Rates

Success rates vary based on the medication used, the patient's age, the underlying diagnosis, and whether ovulation induction is combined with timed intercourse or IUI.

OI = Ovulation Induction; TI = Timed Intercourse; IUI = Intrauterine Insemination

Cumulative Success Rates

The probability of pregnancy accumulates over multiple cycles:

• After 1 cycle: 12-25%
• After 3 cycles: 30-50%
• After 6 cycles: 45-65% (for women under 35 with PCOS)

For women with PCOS specifically, the landmark Legro et al. (2014) trial reported cumulative live birth rates of 27.5% with letrozole and 19.1% with clomiphene over five cycles of treatment. A Cochrane review (Franik et al., 2018) confirmed letrozole's superiority, reporting a higher live birth rate (OR 1.68, 95% CI 1.42-1.99) compared with clomiphene.

Letrozole vs Clomiphene: Success Rate Comparison

From the NICHD trial (Legro et al., NEJM 2014):

India-Specific Data

Indian fertility clinics report outcomes broadly consistent with international data. A study from a large tertiary fertility centre in Mumbai (published in the Journal of Human Reproductive Sciences) reported per-cycle pregnancy rates of 15-22% for letrozole-induced cycles in PCOS patients under 35. Studies from AIIMS and other Indian centres have confirmed letrozole's effectiveness in the Indian population.

The ICMR recognises ovulation induction as first-line treatment and has endorsed evidence-based protocols consistent with international guidelines.

Ovulation induction is the most affordable fertility treatment available in India, making it accessible to a wide socioeconomic range of patients.

Cost by Treatment Type and City

Medication Costs

Monitoring Costs

Total Cost for a Full Treatment Course (3-6 Cycles)

For comparison, a single IVF cycle in India costs Rs 1,50,000-3,00,000. Even a full course of six ovulation induction cycles with IUI costs less than one IVF cycle.

Ovulation induction with oral medications is one of the safest fertility treatments, but understanding the risks is important for informed decision-making.

Side Effects of Clomiphene Citrate

• Hot flushes: 10-20% of patients; due to anti-oestrogenic effects
• Mood changes: Irritability, emotional lability; relatively common
• Headaches: Mild to moderate; usually transient
• Breast tenderness: Related to hormonal changes
• Bloating and abdominal discomfort: Mild ovarian enlargement
• Visual disturbances: Rare (1-2%) but important — blurred vision, light sensitivity, or floaters. If visual symptoms occur, clomiphene should be stopped immediately and not restarted
• Endometrial thinning: The anti-oestrogenic effect on the uterine lining can reduce endometrial thickness below 7 mm, potentially reducing implantation rates. This is the most clinically significant drawback

Side Effects of Letrozole

• Fatigue: The most commonly reported side effect
• Mild headache: Usually resolves within days
• Dizziness: Occasional, mild
• Hot flushes: Less common than with clomiphene
• Joint or muscle aches: Rare at fertility doses (much more common at cancer treatment doses)
• Generally better tolerated: Fewer and milder side effects overall compared to clomiphene

Multiple Pregnancy Risk

This is the most significant medical risk of ovulation induction:

Multiple pregnancies carry significantly increased risks: preterm birth, low birth weight, gestational diabetes, pre-eclampsia, and maternal complications. This is why monitoring and willingness to cancel cycles with more than two to three mature follicles are essential.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is rare with oral medications:

• With letrozole: Extremely rare; almost negligible risk
• With clomiphene: Very rare; less than 1%
• With gonadotropin injections: Higher risk (1-5%), which is why injectable medications require more intensive monitoring

Mild OHSS symptoms (bloating, mild abdominal discomfort) are common and self-limiting. Severe OHSS (fluid accumulation, difficulty breathing, blood clots) is very rare with oral medications.

Long-Term Safety

• Clomiphene: Decades of safety data. No proven association with ovarian cancer, though a theoretical concern from early studies led to the recommendation of limiting use to six cycles. Modern evidence has largely dispelled the ovarian cancer concern, but the six-cycle limit is still widely followed.
• Letrozole: Robust evidence from fertility use over the past 20 years shows no increase in birth defects (contrary to early, flawed animal studies). The Legro et al. (2014) trial and subsequent studies have confirmed no increase in congenital anomalies.

Ovulation induction is a time-limited strategy. Knowing when to escalate treatment is as important as knowing when to start.

Signs It May Be Time to Move On

• Three to six well-monitored cycles with ovulation confirmed but no pregnancy
• Persistent failure to ovulate despite maximum doses
• Age over 37-38 with limited time remaining
• Discovery of additional factors (tubal issues, worsening semen parameters)
• Emotional fatigue and desire for more definitive treatment

Escalation Pathway

The typical treatment progression in India follows this pattern:

1. Ovulation induction + timed intercourse (3-6 cycles)
2. Ovulation induction + IUI (3-4 cycles if not already tried)
3. Gonadotropin injections + IUI (1-3 cycles)
4. IVF/ICSI (the definitive next step)

Your fertility specialist will guide this progression based on your individual response, diagnosis, and goals.

While medication is the primary intervention, certain lifestyle factors can improve your response to ovulation induction:

Weight Management (Especially for PCOS)

Weight loss of even 5-10% of body weight in overweight women with PCOS has been shown to restore ovulation in some cases and significantly improve response to ovulation induction medications. International PCOS guidelines recommend lifestyle intervention as a first step alongside or before medication.

Diet and Nutrition

• A balanced diet with adequate folic acid supplementation (400-800 mcg daily) is essential
• For PCOS, a diet lower in refined carbohydrates and higher in protein and fibre may improve insulin sensitivity and hormonal balance
• Inositol supplementation (particularly myo-inositol and D-chiro-inositol) has shown some benefit in PCOS, though the evidence is still evolving

Stress Management

While stress has not been conclusively proven to cause infertility, the emotional burden of fertility treatment is well-documented. Counselling, support groups, yoga, and mindfulness practices can support mental wellbeing during treatment.

Avoiding Harmful Exposures

• Stop smoking (reduces ovarian reserve and treatment success)
• Limit alcohol consumption
• Avoid excessive caffeine (more than 200 mg/day)
• Both partners should be aware of environmental toxin exposure